article thumbnail

Traditional approaches to growth in biopharma are no longer sustainable

pharmaphorum

Through our recent report, Scientific innovations for more sustainable growth , we analysed over 300 M&A deals made by the world’s top 30 biopharma companies between 2010–2021. Collaboration across the industry is needed now more than ever before across this complex ecosystem – not least because it’s becoming a competitive landscape.

article thumbnail

How AI Can Help Medical Science Liaisons Juggle Their Ever-Growing Responsibilities

PM360

1 And, on average , the FDA approved 60% more drugs between 2010-2019 than the yearly average over the previous decade. In fact, the pharmaceutical industry’s development pipeline has reached an all-time high of 20,109 products under active development at the end of January 2022, an increase of 500 from 2021. The Right Stuff.